RT journal article
T1 Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome
A1 Retamozo, Soledad
A1 Akasbi, Miriam
A1 Brito Zeron, Pilar
A1 Boshc, Xavier
A1 Bove, Albert
A1 Perez de Lis, Marta
A1 Jimenez, Iratxe
A1 Soto Cardenas, Maria Jose
A1 Ramos-Casals, Manel
A1 Soto Cardenas, María José
A1 Gandia, Miriam
A1 Diaz Lagares, Candido
A1 Viñas, Odette
A1 Siso, Antoni
A1 Pérez Alvarez, Roberto
A1 Yagüe, Jordi
A1 Ramos-Casals, Manuel
A2 Cirugía
A2 Medicina
K1 Sjögren’s syndrome
K1 Anri-Ro/SSA antibodies
K1 anti-Ro52 antibodies
AB AbstractOBJECTIVES:To evaluate how determination of antibodies against the Ro52 antigen influences the classification and clinical characterisation of patients with suspected primary Sjögren`s syndrome (SS).METHODS:The cohort study included 187 patients who fulfilled at least four of the six 1993 SS classification criteria, including positive autoantibodies (antinuclear antibodies [ANA], rheumatoid factor [RF], anti-Ro/SSA and/or anti-La/SS-B antibodies) as mandatory criterium. Anti-Ro/SSA antibodies were tested by qualitative ELISA using a commercial assay. Anti-Ro52 antibodies were detected by a semiquantitative ELISA.RESULTS:Anti-Ro52 antibodies were found in 70/187 (37%) patients. A significant percentage of patients with anti-Ro/SSA antibodies were negative for anti-Ro52 antibodies (22%), while 13 patients (12%) were negative for anti-Ro/SSA antibodies but positive for anti-Ro52 antibodies, meaning that they fulfilled the 2002 SS criteria while avoiding the need for a salivary biopsy. Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF. A statistical correlation was found between anti-Ro52 titers and age, gammaglobulin levels, RF titers and serum IgA and IgG. Patients with positive anti-Ro/SSA and anti-Ro52 antibodies had a higher frequency of positive salivary gland biopsy, parotid enlargement and positive RF, and higher levels of serum IgG and IgA levels in comparison with patients with positive anti-Ro/SSA but negative anti-Ro52 antibodies.CONCLUSIONS:Anti-Ro52 antibodies were closely associated with the main clinical, histopathological and immunological features of primary SS. Anti-Ro52 autoantibody testing may help to identify a specific subset of SS patients with more aggressive disease, in whom a closer follow-up and earlier, more robust therapeutic management may be necessary.
PB Clinical and Experimental Rheumatology - 2012, vol. 30, nº 5, pp.  686-692
SN 1593-098X
YR 2012
FD 2012
LK http://hdl.handle.net/10498/39224
UL http://hdl.handle.net/10498/39224
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 08-nov-2026